1. Home
  2. ALT vs ONDS Comparison

ALT vs ONDS Comparison

Compare ALT & ONDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • ONDS
  • Stock Information
  • Founded
  • ALT 1997
  • ONDS 2014
  • Country
  • ALT United States
  • ONDS United States
  • Employees
  • ALT N/A
  • ONDS N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • ONDS Telecommunications Equipment
  • Sector
  • ALT Health Care
  • ONDS Telecommunications
  • Exchange
  • ALT Nasdaq
  • ONDS Nasdaq
  • Market Cap
  • ALT 292.0M
  • ONDS 1.4B
  • IPO Year
  • ALT N/A
  • ONDS N/A
  • Fundamental
  • Price
  • ALT $3.83
  • ONDS $5.86
  • Analyst Decision
  • ALT Strong Buy
  • ONDS Strong Buy
  • Analyst Count
  • ALT 6
  • ONDS 3
  • Target Price
  • ALT $17.40
  • ONDS $4.67
  • AVG Volume (30 Days)
  • ALT 3.0M
  • ONDS 49.3M
  • Earning Date
  • ALT 08-12-2025
  • ONDS 08-12-2025
  • Dividend Yield
  • ALT N/A
  • ONDS N/A
  • EPS Growth
  • ALT N/A
  • ONDS N/A
  • EPS
  • ALT N/A
  • ONDS N/A
  • Revenue
  • ALT $20,000.00
  • ONDS $16,131,404.00
  • Revenue This Year
  • ALT N/A
  • ONDS $246.94
  • Revenue Next Year
  • ALT $761,880.20
  • ONDS $161.09
  • P/E Ratio
  • ALT N/A
  • ONDS N/A
  • Revenue Growth
  • ALT N/A
  • ONDS 75.16
  • 52 Week Low
  • ALT $2.90
  • ONDS $0.57
  • 52 Week High
  • ALT $11.16
  • ONDS $6.19
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • ONDS 79.19
  • Support Level
  • ALT $3.35
  • ONDS $3.20
  • Resistance Level
  • ALT $3.66
  • ONDS $4.33
  • Average True Range (ATR)
  • ALT 0.19
  • ONDS 0.54
  • MACD
  • ALT 0.07
  • ONDS 0.17
  • Stochastic Oscillator
  • ALT 86.18
  • ONDS 89.02

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About ONDS Ondas Holdings Inc.

Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.

Share on Social Networks: